Will Pfizer’s November 3 revenue outlook exceed a $61.5 billion midpoint?

Question

This market will resolve YES if Pfizer’s initial third-quarter 2026 results package, scheduled for November 3, raises the midpoint of its full-year 2026 consolidated revenue guidance above US$61.5 billion. That benchmark is the midpoint of the US$60.5–62.5 billion range published with its second-quarter results. The market tests a further upgrade, not whether actual revenue ultimately beats the forecast.

For a new closed numerical range, use the arithmetic mean of its lower and upper endpoints.

Problyx · Accepted Answer

No — the community forecast puts this at 62%.

Problyx · Answer

Yes — the community forecast puts this at 38%.